Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Hepatitis C virus (HCV) remains a major public health problem, affecting approximately 130 million people worldwide. HCV infection can lead to cirrhosis, hepatocellular carcinoma, and end-stage liver disease, as well as extrahepatic complications such as cryoglobulinemia and lymphoma. Preventative and therapeutic options are severely limited; there is no HCV vaccine available, and nonspecific, IFN-based treatments are frequently ineffective. Development of targeted antivirals has been hampered by the lack of robust HCV cell culture systems that reliably predict human responses. Here, we show the entire HCV life cycle recapitulated in micropatterned cocultures (MPCCs) of primary human hepatocytes and supportive stroma in a multiwell format. MPCCs form polarized cell layers expressing all known HCV entry factors and sustain viral replication for several weeks. When coupled with highly sensitive fluorescence- and luminescence-based reporter systems, MPCCs have potential as a high-throughput platform for simultaneous assessment of in vitro efficacy and toxicity profiles of anti-HCV therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complete Replication of Hepatitis C Virus in Cell Culture
Lindenbach, B. D., Evans, M. J., Syder, A. J., Wölk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R., McKeating, J. A., et al. (2005) · Science · doi:10.1126/science.1114016 · Cited by 2,238 · cited 3×
“Antibodies blocking HCV entry factors, in particular CD81 and SCARB1, have been shown to be effective in vitro (23, 24) and in small animal models (25).”
BackgroundMethodSelf-citationBinding of Hepatitis C Virus to CD81
Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., Weiner, A. J., Houghton, M., Rosa, D., Grandi, G., et al. (1998) · Science · doi:10.1126/science.282.5390.938 · Cited by 2,066 · cited 10×
“Antibodies blocking HCV entry factors, in particular CD81 and SCARB1, have been shown to be effective in vitro (23, 24) and in small animal models (25).”
BackgroundInfluentialClaudin-1 is a hepatitis C virus co-receptor required for a late step in entry
Evans, M. J., von Hahn, T., Tscherne, D. M., Syder, A. J., Panis, M., Wölk, B., Hatziioannou, T., McKeating, J. A., Bieniasz, P. D., & Rice, C. M. (2007) · Nature · doi:10.1038/nature05654 · Cited by 1,232 · cited 4×
“Here, we show that primary human hepatocytes form polarized cell layers in MPCCs. Multidrug resistant protein 2 (MRP2), zona occludens protein 1 (ZO1), and HCV entry factors claudin-1 (CLDN1) (15) and occludin (OCLN) (16, 17), were located in tight junction (TJ)-like structures (canalicular domain), whereas CD26 was l…”
BackgroundInfluentialSelf-citationMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 10×
“, collagen gel sandwich, Matrigel overlay, and randomly distributed cocultures) could not sustain HCV replication, presumably due to a decline in liver-specific phenotype (12) (Fig.”
BackgroundMethodInfluentialSelf-citationThe human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus
Scarselli, E., Ansuini, H., Cerino, R., Roccasecca, R. M., Acali, S., Filocamo, G., Traboni, C., Nicosia, A., Cortese, R., & Vitelli, A. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf529 · Cited by 1,177 · cited 5×
“Antibodies blocking HCV entry factors, in particular CD81 and SCARB1, have been shown to be effective in vitro (23, 24) and in small animal models (25).”
BackgroundInfluentialHuman occludin is a hepatitis C virus entry factor required for infection of mouse cells
Ploss, A., Evans, M. J., Gaysinskaya, V. A., Panis, M., You, H., de Jong, Y. P., & Rice, C. M. (2009) · Nature · doi:10.1038/nature07684 · Cited by 941 · cited 4×
“Pseudoparticles were generated by cotransfection of plasmids encoding (1) an EGFP-encoding provirus (CSGW) or provirus encoding transgene (pTRIP) (2) HIV gag-pol and (3) envelope glycoprotein(s), as previously described (17).”
BackgroundMethodInfluentialSelf-citationBhatia, S. N., Balis, U. J., Yarmush, M. L., & Toner, M. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.14.1883 · Cited by 890 · cited 3×
“Although some of these models provide necessary extracellular matrix cues, they lack crucial heterotypic cell−cell interactions or control over tissue architecture, known to affect liver-specific functions (6, 12).”
BackgroundSelf-citationEvasion of intracellular host defence by hepatitis C virus
Gale, M., & Foy, E. M. (2005) · Nature · doi:10.1038/nature04078 · Cited by 633 · cited 2×
“In those cells that do become infected, HCV is capable of interfering with innate antiviral immunity via NS3-4A-mediated cleavage of critical signaling molecules, including IPS-1, TRIF, and IRF3 (29).”
BackgroundBroadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge
Law, M., Maruyama, T., Lewis, J., Giang, E., Tarr, A. W., Stamataki, Z., Gastaminza, P., Chisari, F. V., Jones, I. M., Fox, R. I., et al. (2008) · Nature Medicine · doi:10.1038/nm1698 · Cited by 591
LeCluyse, E. L. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00135-x · Cited by 477 · cited 1×
“These strategies typically include extracellular matrix manipulations, defined culture media, fluid flow using bioreactors, or alteration of cell– cell interactions by forming 3D spheroidal aggregates or cocultivation with nonparenchymal cell types (6, 12, 13, 14).”
Background
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Self-citationAdvances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment
Huang, G., Li, F., Zhao, X., Ma, Y., Li, Y., Lin, M., Jin, G., Lu, T. J., Genin, G. M., & Xu, F. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00094 · Cited by 825
Engineered In Vitro Disease Models
Benam, K. H., Dauth, S., Hassell, B., Herland, A., Jain, A., Jang, K.-J., Karalis, K., Kim, H. J., MacQueen, L., Mahmoodian, R., et al. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040418 · Cited by 554
The ins and outs of hepatitis C virus entry and assembly
Lindenbach, B. D., & Rice, C. M. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3098 · Cited by 387
Self-citationOrgan-on-a-chip platforms for studying drug delivery systems
Bhise, N. S., Ribas, J., Manoharan, V., Zhang, Y. S., Polini, A., Massa, S., Dokmeci, M. R., & Khademhosseini, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.004 · Cited by 381
A genetically humanized mouse model for hepatitis C virus infection
Dorner, M., Horwitz, J. A., Robbins, J. B., Barry, W. T., Feng, Q., Mu, K., Jones, C. T., Schoggins, J. W., Catanese, M. T., Burton, D. R., et al. (2011) · Nature · doi:10.1038/nature10168 · Cited by 378
Self-citationHepatitis E virus: advances and challenges
Nimgaonkar, I., Ding, Q., Schwartz, R. E., & Ploss, A. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.150 · Cited by 352
Self-citationCell and tissue engineering for liver disease
Bhatia, S. N., Underhill, G. H., Zaret, K. S., & Fox, I. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3005975 · Cited by 309
“In particular, stabilization of hepatocytes within a micropatterned coculture environment enabled recapitulation of the full viral life cycle in vitro (295).”
BackgroundSelf-citationPluripotent stem cell-derived hepatocyte-like cells
Schwartz, R. E., Fleming, H. E., Khetani, S. R., & Bhatia, S. N. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.01.003 · Cited by 282
Self-citationShlomai, A., Schwartz, R. E., Ramanan, V., Bhatta, A., de Jong, Y. P., Bhatia, S. N., & Rice, C. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412631111 · Cited by 258
Self-citationIdentification of small molecules for human hepatocyte expansion and iPS differentiation
Shan, J., Schwartz, R. E., Ross, N. T., Logan, D. J., Thomas, D., Duncan, S. A., North, T. E., Goessling, W., Carpenter, A. E., & Bhatia, S. N. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1270 · Cited by 254
Self-citationMarch, S., Ng, S., Velmurugan, S., Galstian, A., Shan, J., Logan, D. J., Carpenter, A. E., Thomas, D., Sim, B. K. L., Mota, M. M., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.06.005 · Cited by 212
“This platform has been found to be more predictive than existing in vitro liver models for generating and identifying human drug metabolites, drug-induced liver toxicity, and supports the persistent replication of hepatitis C virus (Jones et al., 2010; Ploss et al., 2010; Wang et al., 2010).”
InfluentialSelf-citationBioengineered Liver Models for Drug Testing and Cell Differentiation Studies
Underhill, G. H., & Khetani, S. R. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.11.012 · Cited by 171
Self-citationLong-term culture and expansion of primary human hepatocytes
Levy, G., Bomze, D., Heinz, S., Ramachandran, S. D., Noerenberg, A., Cohen, M., Shibolet, O., Sklan, E., Braspenning, J., & Nahmias, Y. (2015) · Nature Biotechnology · doi:10.1038/nbt.3377 · Cited by 155
Microengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116
“Dose-dependent inhibition of HCVcc replication in MPCCs treated with interferon (IFN)–α or various drugs against viral proteins (B).(108)”
BackgroundMethodSelf-citationFowler, S., Chen, W. L. K., Duignan, D. B., Gupta, A., Hariparsad, N., Kenny, J. R., Lai, W. G., Liras, J., Phillips, J. A., & Gan, J. (2020) · Lab on a Chip · doi:10.1039/c9lc00857h · Cited by 109
Lee, J. B., & Sung, J. H. (2013) · Biotechnology Journal · doi:10.1002/biot.201300086 · Cited by 92
“In a subsequent study, they demonstrated that the co-culture system can support the life cycle of hepatitis C virus: the co-cultured hepatocyte cells expressed known hepatitis C viral entry factors and sustained viral replication for several weeks [46].”
BackgroundEngineered Liver Platforms for Different Phases of Drug Development
Ware, B. R., & Khetani, S. R. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.001 · Cited by 90
“Specifically, MPCCs can be infected with several pathogens, such as hepatitis B virus [22], hepatitis C virus [23], and malaria [24], and they can be used to screen for glucose-lowering diabetes drugs [25].”
BackgroundSelf-citationLong-term culture of human liver tissue with advanced hepatic functions
Ng, S. S., Xiong, A., Nguyen, K., Masek, M., No, D. Y., Elazar, M., Shteyer, E., Winters, M. A., Voedisch, A., Shaw, K., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90853 · Cited by 32
Developing Liver Microphysiological Systems for Biomedical Applications
Wang, J., Wu, X., Zhao, J., Ren, H., & Zhao, Y. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302217 · Cited by 27
Sun, Y., Yin, S., Cui, J., Wang, Z., Han, Y., Ma, D., Wang, S., Wu, J., Cao, Y., Jiang, C., et al. (2024) · Nano Research · doi:10.1007/s12274-023-5940-3 · Cited by 13
Choi, J. E., Hur, W., Kim, J.-H., Li, T. Z., Lee, E. B., Lee, S. W., Kang, W., Shin, E.-C., Wakita, T., & Yoon, S. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091958 · Cited by 12
Metadata
- Authors
- Ploss, A., Khetani, S. R., Jones, C. T., Syder, A. J., Trehan, K., Gaysinskaya, V. A., Mu, K., Ritola, K., Rice, C. M., & Bhatia, S. N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-02
- Volume
- 107
- Issue
- 7
- Pages
- 3141-3145
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2156213033
- Cited by
- 211
- References
- 29
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.